Table 2.
Baseline characteristics of 294 patients according to the diagnosis.
| Total (n = 294) | IPF (n = 121) | Non-IPF-ILDs (n = 173)a | P-value | |
|---|---|---|---|---|
| Age | 68.2 ± 12.9 | 72.5 ± 10.0 | 65.2 ± 13.9 | < 0.001 |
| Sex, male (%) | 192 (65.3) | 90 (74.4) | 102 (59.0) | 0.006 |
| Smoking | 162 (58.1) | 79 (68.1) | 83 (50.9) | 0.004 |
| PFT | ||||
| FVC | 83.7 ± 28.4 | 81.1 ± 18.2 | 80.8 ± 19.7 | 0.899 |
| DLCO | 74.1 ± 23.6 | 78.7 ± 21.1 | 72.4 ± 24.4 | 0.089 |
| Tumor marker | ||||
| CEA (n = 266) | 2.8 (1.7–4.9) | 3.0 (2.2–4.8) | 2.7 (1.5–5.1) | 0.236 |
| CEA (%)b | 65 (24.4) | 24 (22.2) | 41 (25.9) | 0.487 |
| CA19-9 (n = 154) | 14.1 (5.9–34.8) | 17.3 (6.3–80.3) | 11.3 (5.7–31.0) | 0.166 |
| CA19-9 (%)b | 37 (24.0) | 16 (26.7) | 21 (22.3) | 0.556 |
| CA125 (n = 55) | 24.2 (11.2–59.4) | 26.5 (17.4–65.0) | 21.3 (10.7–60.1) | 0.405 |
| CA125 (%)b | 20 (36.4) | 6 (46.2) | 14 (33.3) | 0.401 |
Data are expressed as mean ± SD, median (interquartile range), or frequency (%).
IPF idiopathic pulmonary fibrosis, ILD interstitial lung disease, PFT pulmonary function test, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, ILD interstitial lung disease, CEA carcinoembryonic antigen, CA carbohydrate antigen.
aNon-IPF-ILDs: idiopathic nonspecific interstitial pneumonia (n = 16), cryptogenic organizing pneumonia (n = 11), connective tissue disease associated ILDs (n = 51), hypersensitivity pneumonitis (n = 1), unclassifiable ILD (n = 70), others (n = 24).
bProportion of abnormal tumor marker values (normal range: CA 19-9, 0–37 U/mL; CA 125, 0–35 U/mL; CEA, 0–5 ng/mL).